FDAnews Device Daily Bulletin

GUIDANT UPDATED TO 'BUY'

Nov. 9, 2005
A A

Analyst Glenn Novarro of Banc of America Securities upgrades Guidant from "neutral" to "buy," while reducing his estimates for the company. The target price has been reduced from $69 to $66.
Newratings